12:00 AM
 | 
Oct 12, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Azedra: Additional Phase I data

A dose-escalation Phase I trial in 21 patients showed that Azedra produced 3 partial responses and 14 cases of stable disease at 1 year. Molecular Insight said the data support an MTD of 8 mCi/kg....

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >